Business Wire

Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

Christian Seitz Thursday, September 12, 06:15 PM to 7:15 PM CT, Location: Riverside East, Riverside West/South – Exhibit Hall Level- East Tower Poster #122: “Do sleep disturbances have an impact on ...
Morningstar

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and ...
Business Wire

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the ...
GEN

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...
Reuters

Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal

BERLIN, Aug 12 (Reuters) - German pharmaceutical group Bayer (BAYGn.DE), opens new tab announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology ...
FierceBiotech

Boehringer and Bayer's oral meds deliver in early HER-2 mutant lung cancer studies

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor 2 (HER2), which drives their disease progression. Treatment options are ...
Nasdaq

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1 In OASIS 1 and OASIS 2, ...